Pancreatitis, Pancreatic and Thyroid Cancer Associated with Januvia
Januvia May Increased Cancer Risks. Our firm is investigating potential lawsuits on behalf of patients who suffered from pancreatitis, pancreatic cancer or thyroid cancer related to the use of glucagon-like peptide-1-based therapies such as Januvia (sitagliptin). Januvia is a prescription medicine used along with diet and exercise to … [Read more...]
DPP-4 Inhibitor Type 2 Diabetes Drugs Associated with Serious Side Effects
DPP-4 Inhibitor Serious Side Effects. Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), a class of oral diabetes medications that includes Januvia, Onglyza, Trajenta, and Nesina, treat Type 2 diabetes by blocking DPP-4. Oral DPP-4 inhibitors work by increasing incretin levels in the pancreas which, in turn, inhibits the … [Read more...]
DPP-4 Inhibitor Type 2 Diabetes Drugs Associated with Serious Side Effects
Diabetes Drugs Serious Side Effects. Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), a class of oral diabetes medications that includes Januvia, Onglyza, Trajenta, and Nesina, treat Type 2 diabetes by blocking DPP-4. Oral DPP-4 inhibitors work by increasing incretin levels in the pancreas which, in turn, inhibits the … [Read more...]
Link Between Januvia and Pancreatic Cancer
Potential Link Between Januvia and Pancreatic Cancer. Federal health officials are set to launch an investigation into a possible link between the type 2 diabetes drug Januvia (sitagliptin) and a risk of pancreatic cancer. According to a New York Times report, the U.S. Food and Drug Administration (FDA) is acting on the research … [Read more...]
Merck’s Januvia Sales Drop
Merck’s Januvia Drop in Quarterly Sales. Drug maker Merck & Co. Inc. just reported an unexpected drop in the quarterly sales of its Type II diabetes drug Januvia. Januvia is Merck’s fastest- and greatest-selling product since it was approved in 2006. It is the one product that often drives the drug maker’s quarterly … [Read more...]
Byetta, Januvia Cancer Risks Debated
Byetta, Januvia Cancer Risks. The uncertainty surrounding type 2 diabetes drugs like Byetta and Januvia have prompted calls for more studies of glucagon-like peptide 1 (GLP-1) therapies. A recent study has tied Byetta and Januvia to a possible increased risk of pancreatic cancer, but other researchers, along with the drug's … [Read more...]
